Ind-Swift Labs reports no deviation in ₹255.61 Cr preferential issue funds
Ind-Swift Laboratories Limited confirmed no deviation or variation in the use of funds raised through its Preferential Issue of Convertible Warrants for the quarter ended March 31, 2026. The original issue size was ₹314.60 Crores, but the actual realizable proceeds have been revised to ₹255.61 Crores. This adjustment follows the forfeiture of ₹19.66 Crores from SARAL INCORPORATED VCC SUB FUND 1 due to unexercised warrants and an additional ₹58.99 Crores becoming non-receivable from the same allottee. The company utilized ₹232.02 Crores as of March 31, 2026, towards business expansion, investment in subsidiaries, working capital, and general corporate purposes. The Nil Statement of Deviation was duly reviewed by the Audit Committee.
Key Highlights
- No deviation in preferential issue fund utilization for Q4 FY26 reported.
- Total realizable proceeds revised to ₹255.61 Cr from original ₹314.60 Cr.
- ₹19.66 Cr forfeited due to unexercised warrants; ₹58.99 Cr non-receivable.
- ₹232.02 Cr utilized for expansion, investment, working capital, and general corporate purposes.
- Statement of Deviation reviewed and approved by the Audit Committee.
Price Impact
More from INDSWFTLAB